Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone substitution for ethambutol in a standard six month… changes serious adverse events compared with standard regimen (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in serious adverse events compared with standard regimen (low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes serious adverse events compared with standard regimen alone (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · patients undergoing laparoscopic cholecystectomy.
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether miniport laparoscopic cholecystectomy changes serious adverse events compared with standard port laparoscopic cholecystectomy (very low certainty).
1 finding from 1 review
Serious adverse events · high‐risk surgical patients with acute calculous cholecystitis.
It is very uncertain whether intervention changes serious adverse events compared with control (very low certainty).
1 finding from 1 review
Serious adverse events · people with biliary colic
It is very uncertain whether early changes serious adverse events compared with delayed laparoscopic cholecystectomy (very low certainty).
1 finding from 1 review
Serious adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
Topiramate 200 to 400 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.6, 1.3]
1586 participants
Moderate
Serious adverse events
Continuous showed no clear difference in serious adverse events compared with intermittent Antibiotic Infusions (low certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Serious adverse events · patients with restenosis after percutaneous coronary intervention in coronary heart disease
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) (high certainty).
1 finding from 1 review
Serious adverse events · patients with restenosis after percutaneous coronary intervention in coronary heart disease
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) plus placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with mild acute gallstone pancreatitis
It is very uncertain whether early changes serious adverse events compared with delayed laparoscopic cholecystectomy (very low certainty).
1 finding from 1 review
Serious adverse events · patients with fibromyalgia
Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · People with giardiasis infection
1 finding from 1 review
Intervention not reported
Serious adverse events · People with giardiasis infection
1 finding from 1 review